FDA Inspection 1261706 — The Center for Reproductive Endocrinology
The FDA completed an inspection of The Center for Reproductive Endocrinology on February 12, 2025 in Dallas, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 12, 2025
- Fiscal Year
- 2025
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Dallas, TX (United States)